Live Breaking News & Updates on Decipher Prostate Biopsy

Stay updated with breaking news from Decipher prostate biopsy. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Veracyte, Inc. (NASDAQ:VCYT) Receives Average Recommendation of "Moderate Buy" from Brokerages

Shares of Veracyte, Inc. (NASDAQ:VCYT – Get Free Report) have been assigned an average rating of “Moderate Buy” from the five ratings firms that are presently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The average 12 […] ....

Hong Kong , United States , William Blair , International Assets Investment Management , Morgan Stanley , Needham Company , Veracyte Inc , Russell Investments Group Ltd , Veracyte Company Profile , Hong Kong Ltd , China Universal Asset Management Co , Get Free Report , Investments Group , Kong Ltd , Assets Investment Management , Universal Asset Management , Trading Down , Get Free , Afirma Genomic Sequencing Classifier , Decipher Prostate Biopsy , Radical Prostatectomy , Prosigna Breast Cancer Assay , Percepta Nasal Swab Test , Envisia Genomic Classifier , Veracyte Daily ,

Veracyte (NASDAQ:VCYT) Rating Reiterated by William Blair

William Blair reiterated their outperform rating on shares of Veracyte (NASDAQ:VCYT – Free Report) in a research report sent to investors on Friday, RTT News reports. William Blair also issued estimates for Veracyte’s Q2 2025 earnings at ($0.01) EPS and FY2025 earnings at $0.00 EPS. A number of other brokerages have also issued reports on […] ....

Hong Kong , William Blair , Russell Investments Group Ltd , Veracyte Inc , Needham Company , International Assets Investment Management , Morgan Stanley , China Universal Asset Management Co , Hong Kong Ltd , Veracyte Company Profile , Free Report , Moderate Buy , Investments Group , Kong Ltd , Assets Investment Management , Universal Asset Management , Get Free Report , Afirma Genomic Sequencing Classifier , Decipher Prostate Biopsy , Radical Prostatectomy , Prosigna Breast Cancer Assay , Percepta Nasal Swab Test , Envisia Genomic Classifier , Immunoscore Colon Cancer , Veracyte Daily , Nasdaq Vcyt ,

Needham & Company LLC Boosts Veracyte (NASDAQ:VCYT) Price Target to $33.00

Veracyte (NASDAQ:VCYT – Get Free Report) had its price target lifted by Needham & Company LLC from $30.00 to $33.00 in a research report issued on Friday, Benzinga reports. The firm currently has a “buy” rating on the biotechnology company’s stock. Needham & Company LLC’s price target suggests a potential upside of 35.58% from the […] ....

William Blair , Veracyte Inc , China Universal Asset Management Co , Morgan Stanley , Needham Company , Legato Capital Management , York Mellon Corp , Assetmark Inc , Get Free Report , Trading Down , Universal Asset Management , Capital Management , New York Mellon Corp , Afirma Genomic Sequencing Classifier , Decipher Prostate Biopsy , Radical Prostatectomy , Prosigna Breast Cancer Assay , Percepta Nasal Swab Test , Envisia Genomic Classifier , Immunoscore Colon Cancer , Veracyte Daily , Nasdaq Vcyt , Boost Price Target , Needham Amp Company Llc ,

Fiera Capital Corp Increases Holdings in Veracyte, Inc. (NASDAQ:VCYT)

Fiera Capital Corp Increases Holdings in Veracyte, Inc. (NASDAQ:VCYT)
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

William Blair , Exchange Commission , Needham Company , Synovus Financial Corp , Financial Services Group Inc , Veracyte Inc , Morgan Stanley , Fiera Capital Corp , Metlife Investment Management , Jpmorgan Chase Co , Goldman Sachs Group , Free Report , Capital Corp , Services Group , Life Investment Management , Financial Corp , Afirma Genomic Sequencing Classifier , Decipher Prostate Biopsy , Radical Prostatectomy , Prosigna Breast Cancer Assay , Percepta Nasal Swab Test , Envisia Genomic Classifier , Immunoscore Colon Cancer , Visit Holdingschannel , Veracyte Daily ,

Brokerages Set Veracyte, Inc. (NASDAQ:VCYT) Target Price at $29.50

Brokerages Set Veracyte, Inc. (NASDAQ:VCYT) Target Price at $29.50
etfdailynews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from etfdailynews.com Daily Mail and Mail on Sunday newspapers.

Hong Kong , William Blair , Needham Company , Bergankdv Wealth Management , Hong Kong Ltd , International Assets Investment Management , Morgan Stanley , Veracyte Inc , Harbor Capital Advisors Inc , Russell Investments Group Ltd , Get Free Report , Investments Group , Kong Ltd , Capital Advisors , Get Free , Afirma Genomic Sequencing Classifier , Decipher Prostate Biopsy , Radical Prostatectomy , Prosigna Breast Cancer Assay , Percepta Nasal Swab Test , Envisia Genomic Classifier , Immunoscore Colon Cancer , Veracyte Daily ,